BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• Business

  Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

  Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter of 2023.

  May 8, 2023

   · 

  13 min read
• Business

  Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress

  Annexon, Inc. reported first quarter 2023 financial results and highlighted recent progress across its portfolio of complement therapies.

  May 8, 2023

   · 

  9 min read
• Business

  Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

  Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.

  May 8, 2023

   · 

  19 min read
• Press Releases

  Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

  Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

  May 8, 2023

   · 

  21 min read
• Business

  Aptose Reports Results for the First Quarter 2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced financial results for first quarter ended March 31, 2023, and provided a corporate update.

  May 8, 2023

   · 

  12 min read
• Business

  FibroGen Reports First Quarter 2023 Financial Results

  FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the company’s recent developments.

  May 8, 2023

   · 

  10 min read
• Press Releases

  Maravai LifeSciences Reports First Quarter 2023 Financial Results

  Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, reported financial results for the first quarter ended March 31, 2023, together with other business updates.

  May 8, 2023

   · 

  17 min read
• Business

  CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

  CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.

  May 8, 2023

   · 

  18 min read
• Business

  Progyny, Inc. Announces First Quarter 2023 Results

  Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”) today announced its financial results for the three-month period ended March 31, 2023 (“the first quarter of 2023”) as compared to the three-month period ended March 31, 2022 (“the first quarter of 2022” or “the prior year period”).

  May 8, 2023

   · 

  22 min read
• Business

  Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

  Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that its first quarter 2023 financial results will be released on Monday, May 15, 2023 before the U.S. financial markets open.

  May 8, 2023

   · 

  1 min read